News ICER says AZ's new hypertension drug too expensive ICER says that AstraZeneca's first-in-class Baxfendy and a rival drug from Mineralys are not cost-effective as therapies for resistant hypertension.
News AZ gets first okay for new hypertension drug baxdrostat AstraZeneca is the first company to get FDA approval for an aldosterone synthase inhibitor for hypertension, ahead of rival Mineralys.
News GSK planning 1,200 job cuts in Belgium, says paper GSK is said to be preparing to cut around 1,200 positions from its workforce in Belgium as part of a cost-saving programme launched by CEO Luke Miels.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.